David Lane (oncologist)

Source: Wikipedia, the free encyclopedia.
For other people named David Lane, see David Lane (disambiguation).

Sir
David Lane
FRSE
Born
David Philip Lane

(1952-07-01) 1 July 1952 (age 71)[2]
Wimbledon, London
, England
Alma mater
  • University College, London
Known forDiscovery of p53
AwardsPaul Ehrlich and Ludwig Darmstaedter Prize (1998)
Scientific career
Fieldsimmunology
Institutions
Doctoral studentsSara Mole[1]

Sir David Philip Lane

FRSE (born 1 July 1952) is a British immunologist, molecular biologist and cancer researcher. He is currently working in the Department of Microbiology, Tumor and Cell Biology at the Karolinska Institute and is Chairman of Chugai Pharmabody. He is best known for the discovery of p53, one of the most important tumour suppressor genes.[3]

Education

Lane completed his undergraduate and postgraduate degrees at

University College, London where he studied auto-immunity under the supervision of Avrion Mitchison
.

Career and research

Lane carried out

Imperial College, London
, then moving to the ICRF laboratories at Clare Hall before moving in 1990 to the University of Dundee to help establish the CRC laboratories there.

He has played an active part in UK science, sitting at various times on the scientific committee of the CRC, the Cell Board of the MRC, and on the council of the ICRF. He is dedicated to the successful translation of research for patient benefit and participated in the early discussions around the scientific benefits of the merger of ICRF and CRC, before serving as chief scientist to their successor, Cancer Research UK, until 2010.[citation needed]

Lane founded the Dundee-based Biotechnology company, Cyclacel Ltd and was the chief scientific officer from 1996 to 2004. From 2004 to 2007, he was the executive director of the Institute of Molecular & Cell Biology (IMCB) in Singapore.[citation needed]

Sir David was chief scientist of Singapore's Agency for Science, Technology and Research (A*STAR, Singapore). He is also professor of tumour suppressor biology at the Department of Microbiology, Tumor and Cell Biology at the Karolinska Institute, where he is heading a research group.

Lane has published more than 350 research articles that have been cited over 100,000 times and is internationally recognised for his original discovery of the

p53 protein SV40 T antigen complex and for his many subsequent contributions to the p53 field. The p53 gene is the most frequently altered gene in human cancer with more than half of all cancers having mutant p53. He is co-author with Ed Harlow of the most successful practical guide to the use of immunochemical methods. The "Antibodies" manual has sold over 40,000 copies.[citation needed
]

Awards and honours

Lane is a member of the

Academy of Medical Sciences
.

He has won many international prizes for his work including the

Paul Ehrlich Prize and the Cancer Research UK Lifetime Achievement Prize (2012).[4]
He has been awarded honorary degrees from the Universities of Toulouse, Birmingham, Aberdeen, Stirling, Abertay, Brno and Nottingham. He has also been recognized for his business acumen with the award of Emerging Entrepreneur of the year.

On 29 September 2016 The John Fisher School opened the Sir David Lane building.[5]

He was knighted for his contribution to cancer research in the New Year honours list in January 2000.

References

  1. OCLC 930654055. Copac 29526616. Free access icon
  2. ISBN 0-9711966-2-1
    .
  3. doi:10.7750/BioDiscovery.2012.1.5. Archived from the original
    (PDF) on 9 June 2016. Retrieved 18 May 2016.
  4. ^ "Our researcher prizes". Cancer Research UK. 3 February 2015. Retrieved 22 February 2018.
  5. ^ "In the Right Lane, Callum Lawlor, The John Fisher School" This is local London. 2016-10-23. Retrieved 2018-04-04

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=David_Lane_(oncologist)&oldid=1211930140"